Predicting which breast cancer patients respond to CDK4/6i therapy is crucial, but current methods are unreliable. This study explores using delta radiomics to analyze CT scans before and after treatment. The results show promise in identifying responders early, potentially leading to personalized treatment plans and avoiding unnecessary side effects for patients. This could improve patient selection for CDK4/6i treatments and improve clinical trial design to identify non-responders well before long-term trial endpoints mature.
Read the full article HERE
Read the full article HERE
